ADVENZYMES302.20

Advanced Enzyme Tech Ltd.

· Pharma & Health
₹ CrorePeersAARTIPHARMAARTIDRUGSAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹3,382 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)348.58354.52333.00333.00
Receivable Days (DSO)57.6766.1370.9870.98
Payable Days (DPO)37.0038.7775.0671.20
Cash Conversion Cycle (days)369.25381.88328.92332.78
Working Capital Turnover0.890.810.800.80
Asset Turnover0.410.390.410.41
Cash Conversion (CFO/Net Income)1.031.060.900.90
CFO/EBITDA0.690.730.680.68
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.